Great. Good morning, everyone. Thanks for joining us here at day 2 of the Leerink Partners Global Healthcare Conference. My name is Tom Smith. I'm one of the senior biotech analysts here at Leerink.
Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results